Search the Newsreel

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Average Recommendation of "Moderate Buy" from Brokerages

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) has received an average "Moderate Buy" recommendation from analysts, with an average 12-month price target of $35.57. The company recently exceeded quarterly earnings and revenue expectations, reporting $0.11 EPS against an anticipated $0.06 and $129.86 million in revenue versus $118.85 …

DOCU Stock Slides After-Hours As Full Year Guidance Meets, But Fails To Exceed Expectations

DocuSign Jumps 8.4% Amid Sector-Wide Rally

DocuSign (NASDAQ: DOCU) saw its shares jump 8.4% to $62.99 on August 13, 2026, as part of a broad sector-wide rally in software application companies. This surge was not driven by company-specific news but by a general shift in investor sentiment, with peers like …

Pacific Current Group slips again as thin newsflow and a concentrated register keep investors guessing

Summary of Hong Kong Stock Ratings: China Merchants Securities (Hong Kong) Maintains Buy Rating on AIA

Canadian Utilities (TSE:CU) Stock Crosses Above Two Hundred Day Moving Average - Here's Why

CuriosityStream Inc. (CURI) Stock Price | Live Quotes & Charts | NASDAQ

This page provides live quotes and charts for CuriosityStream Inc. (CURI) stock, showing its current price of $3.55, a decrease of 11.03%. It also includes information on analyst ratings, which are currently unavailable, and states that earnings information for the company is not yet …

Arcus Biosciences, Inc. Stock 12‑Month Price Target Raised to $38.82, Implies 35% Upside

Arcus Biosciences, Inc. (RCUS) has seen its average 12-month price target raised from $38.33 to $38.82 by 11 analysts, with forecasts ranging from $23 to $47 per share. This new target implies a potential upside of approximately 35% from its August 13 closing price. …

KTOS|Kratos Defense and Security Solutions Inc|Price:64.580|Chg%:+1.790

Cummins India Share Price - Live NSE: CUMMINSIND Stock Price & Chart

Assicurazioni Generali Aktie | IT0000062072 | ETR:ASG | News & Aktienkurs | FRA:ASG

Scully Royalty Ltd (SRL) Earnings Forecast: Future EPS & Revenue Growth Estimates

Atlanticus (ATLC) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 5:00 p.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Jeffrey HowardChief Financial Officer - William McCamey TAKEAWAYS Total Operating Revenue and Other Income -- $744.3 million, an 89% increase from the …

Atlanticus (ATLC) Is Down 13.2% After Q2 Earnings Beat And Faster Mercury Integration Progress – Has The Bull Case Changed?

Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update

Celcuity Inc. announced its Q2 2026 financial results, highlighted by the FDA approval of REVTORPYK (gedatolisib) for HR+/HER2- PIK3CA Wild-Type breast cancer and its inclusion in NCCN guidelines. The company plans a commercial launch for REVTORPYK in late Q3 2026 and intends to submit …

Securitize Q2 Earnings Call Highlights

Key Points Interested in Securitize Holdings? Here are five stocks we like better. Q2 revenue fell 5% year over year to $14.4 million, as lower tokenization revenue offset 3% growth in asset servicing. Securitize lowered its 2026 revenue outlook to $70 million–$80 million, citing …

(YOU) Volatility Zones as Tactical Triggers

This article analyzes Clear Secure Inc. Class A (NYSE: YOU), identifying weak near and mid-term sentiment despite a positive long-term outlook. It provides AI-generated trading strategies including position trading, momentum breakout, and risk hedging with specific entry, target, and stop-loss levels. The analysis emphasizes …

Accuracy Shipping consolidated net profit rises 17.07% in the June 2026 quarter

Truist Financial Initiates Kratos Defense & Security Solutions(KTOS.US) With Buy Rating, Announces Target Price $104

Truist Financial has initiated coverage on Kratos Defense & Security Solutions (KTOS.US) with a Buy rating. The financial firm also set a target price of $104 for the stock, indicating confidence in the company's future performance.

Cubex Tubings standalone net profit rises 7.32% in the June 2026 quarter

Abacus Group (ASX:ABG) Dividend Watch: Can a 9.34% Yield Reflect Long-Term Income Potential?

Scully Royalty names interim CEO and CFO as chairman steps in during leadership search

Scully Royalty Ltd. has appointed Chairman Michael Smith as interim CEO and CFO, replacing Samuel Morrow, who will remain a non-executive director. Smith will oversee executive functions while the company searches for permanent leadership. The company has committed to maintaining disciplined financial oversight during …

NextCure stock rating reiterated at Buy by H.C. Wainwright

H.C. Wainwright reiterated a Buy rating and a $20.00 price target for NextCure Inc. (NASDAQ: NXTC) following investor enthusiasm surrounding its announced reverse merger with Avere Therapeutics. The combined entity will operate as Avere Therapeutics and trade as AVRX, with the transaction expected to …

5 Revealing Analyst Questions From CLEAR Secure’s Q2 Earnings Call

5 Revealing Analyst Questions From CLEAR Secure's Q2 Earnings Call CLEAR Secure's second quarter was marked by strong revenue growth and notable operating margin improvement, which contributed to a positive market reaction. Management attributed these results to increased adoption of its secure identity platform, …

Cue Biopharma, Inc. SEC Filing (Aug 14, 2026)

This article reports on a Form 144 SEC filing by Cue Biopharma, Inc. (CUE) on August 14, 2026. The filing indicates a proposed sale of 8,829 shares of common stock with an aggregate market value of $266,106.06, acquired through Restricted Stock Units vesting under …

Patrick Burnett Sells 6,700 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock

Patrick Burnett, an insider at Arcutis Biotherapeutics (NASDAQ:ARQT), sold 6,700 shares of the company's stock for $174,736 on August 12th, reducing his direct stake by over 5%. This sale follows two earlier transactions in August where he sold an additional 9,255 shares. Despite the …

Marcus & Millichap arranges $3.9 million sale of 56,000 s/f 470 Pine St.

Marcus & Millichap successfully brokered the sale of 470 Pine St., a 56,000 square foot multi-tenant building in downtown Manchester, NH, for $3.9 million. The property, originally built in 1924 and converted from a mill to a school, is fully occupied by three educational …

Abacus Group to Mark Down Storage King Stake After Accounting Reclassification

This Mercury Systems Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

This article highlights five new stock initiations by Wall Street analysts. Notably, Piper Sandler initiated coverage on Unusual Machines Inc., LightPath Technologies Inc., and Mercury Systems Inc. with an Overweight rating. Chardan Capital initiated QumulusAI Inc. with a Buy rating, and JP Morgan started …

Arcutis Biotherapeutics EVP, CMO Burnett sells $394,896 in stock By Investing.com

Patrick Burnett, EVP and CMO of Arcutis Biotherapeutics (NASDAQ:ARQT), sold shares worth $394,896 in two transactions on August 11 and 12, 2026, following the exercise of stock options. The company's shares have seen a 61.64% return over the past year, and recent Q2 2026 …

Curtiss-Wright Shares Dropping 5.3% on Curtiss-Wright (CW) Q2 2026 Earnings Call Transcript

ICU Medical (ICUI) Q2 2026 Earnings Call Transcript

Clever Culture Systems Seeks ASX Quotation for 2.6 Million New Shares

Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)’s Cancer Drug Partnership Create a New Treatment Standard?

On July 22, Arcus Biosciences, Inc. (NYSE:RCUS) and Summit Therapeutics Inc. (NASDAQ:SMMT) announced a major clinical trial collaboration to combine Arcus's casdatifan (an investigational HIF-2α inhibitor) with Summit's ivonescimab (an investigational PD-1/VEGF bispecific antibody). The study aims to evaluate the safety and efficacy of …

ICU Medical VP Daniel Woolson sells $982,264 in stock

Daniel Woolson, VP, GM-Infusion Capital at ICU Medical Inc. (NASDAQ:ICUI), sold 5,417 shares of the company's common stock for $982,264 on August 13, 2026, at $181.33 per share. This sale occurred as ICUI shares are near their 52-week high, following strong Q2 results where …

Arcus Biosciences (RCUS) Reported Q2 2026 Results, Is The Stock A Bargain?

Arcus Biosciences reported Q2 2026 results with $41 million in revenue and a $91 million net loss, along with new full-year revenue guidance. The stock has seen significant price returns (16.07% in 90 days, 24.35% YTD), and a current valuation suggests it is 24% …